🌍·Jun 15Industry
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
Publisher
A
Aptose Biosciences
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Aptose Biosciences
- Region
- Global
- Scope
- Industry
- Published
- June 15, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on aptose.com
Leave the platform to read the original full article on the publisher site.
Source: Aptose Biosciences
Scope: Industry
Related coverage